Technical Analysis for NLSP - NLS Pharmaceutics Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical NLSP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -3.87% | |
| Fell Below 50 DMA | Bearish | -3.87% | |
| MACD Bearish Centerline Cross | Bearish | -3.87% | |
| Wide Bands | Range Expansion | -3.87% | |
| MACD Bullish Centerline Cross | Bullish | -10.03% | |
| Wide Bands | Range Expansion | -10.03% | |
| NR7 | Range Contraction | -11.75% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | about 4 hours ago |
| Possible NR7 | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Down 2 % | about 9 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Sleep Disorders Attention Deficit Hyperactivity Disorder Amphetamine Drug Therapies Narcolepsy Adhd Methylphenidate Cataplexy Childhood Psychiatric Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Sleep Disorders Attention Deficit Hyperactivity Disorder Amphetamine Drug Therapies Narcolepsy Adhd Methylphenidate Cataplexy Childhood Psychiatric Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.35 |
| 52 Week Low | 2.06 |
| Average Volume | 3,932,983 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 3.53 |
| 20-Day Moving Average | 3.44 |
| 10-Day Moving Average | 3.55 |
| Average True Range | 0.33 |
| ADX | 15.01 |
| +DI | 20.65 |
| -DI | 22.72 |
| Chandelier Exit (Long, 3 ATRs ) | 3.07 |
| Chandelier Exit (Short, 3 ATRs ) | 3.82 |
| Upper Bollinger Band | 4.04 |
| Lower Bollinger Band | 2.84 |
| Percent B (%b) | 0.33 |
| BandWidth | 35.02 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0035 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.56 | ||||
| Resistance 3 (R3) | 3.58 | 3.49 | 3.51 | ||
| Resistance 2 (R2) | 3.49 | 3.41 | 3.48 | 3.49 | |
| Resistance 1 (R1) | 3.36 | 3.35 | 3.32 | 3.34 | 3.47 |
| Pivot Point | 3.27 | 3.27 | 3.25 | 3.26 | 3.27 |
| Support 1 (S1) | 3.14 | 3.19 | 3.10 | 3.12 | 2.99 |
| Support 2 (S2) | 3.05 | 3.13 | 3.04 | 2.97 | |
| Support 3 (S3) | 2.92 | 3.05 | 2.96 | ||
| Support 4 (S4) | 2.90 |
